Form 8-K - Current report:
SEC Accession No. 0001437749-25-010191
Filing Date
2025-03-31
Accepted
2025-03-31 16:12:22
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20250325_8k.htm   iXBRL 8-K 30459
2 EXHIBIT 99.1 ex_796258.htm EX-99.1 114873
  Complete submission text file 0001437749-25-010191.txt   310396

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvph-20250331.xsd EX-101.SCH 4041
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20250331_def.xml EX-101.DEF 13413
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20250331_lab.xml EX-101.LAB 17610
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20250331_pre.xml EX-101.PRE 13390
17 EXTRACTED XBRL INSTANCE DOCUMENT rvph20250325_8k_htm.xml XML 4754
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 25793361
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)